Neovascular Age-related Macular Degeneration (nAMD)

Ophthalmology
4
Pipeline Programs
5
Companies
5
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
1
0
2
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
1100%
+ 4 programs with unclassified modality

Competitive Landscape

5 companies ranked by most advanced pipeline stage

4D Molecular Therapeutics
1 program
1
4D-150 IVTPhase 31 trial
Active Trials
NCT07064759Recruiting480Est. Feb 2029
Sandoz
SandozAustria - Kundl
1 program
1
SOK583A1Phase 31 trial
Active Trials
NCT05282004CompletedEst. Sep 2022
AbbVie
AbbVieNORTH CHICAGO, IL
1 program
1
RanibizumabPhase 2Monoclonal Antibody1 trial
Active Trials
NCT04514653Active Not Recruiting146Est. Feb 2027
Alcon
AlconFORT WORTH, TX
1 program
1
AR-14034 SR implant lower dosePhase 1/21 trial
Active Trials
NCT05769153RecruitingEst. Oct 2027
Bayer
BayerLEVERKUSEN, Germany
1 program
AfliberceptN/A1 trial
Active Trials
NCT06929143Active Not Recruiting3,000Est. Jul 2027

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
4D Molecular Therapeutics4D-150 IVT
SandozSOK583A1
AbbVieRanibizumab
AlconAR-14034 SR implant lower dose
BayerAflibercept

Clinical Trials (5)

Total enrollment: 3,626 patients across 5 trials

Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration

Start: Jul 2025Est. completion: Feb 2029480 patients
Phase 3Recruiting

Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Vial Kit

Start: May 2022Est. completion: Sep 2022
Phase 3Completed

RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD)

Start: Aug 2020Est. completion: Feb 2027146 patients
Phase 2Active Not Recruiting
NCT05769153AlconAR-14034 SR implant lower dose

Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)

Start: Dec 2023Est. completion: Oct 2027
Phase 1/2Recruiting
NCT06929143BayerAflibercept

A Study to Learn More About the Use of Aflibercept in Routine Medical Practice in Japanese Participants With Neovascular Age-related Macular Degeneration and Diabetic Macular Edema

Start: Apr 2025Est. completion: Jul 20273,000 patients
N/AActive Not Recruiting

Related Jobs in Ophthalmology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 late-stage (Phase 3) programs — potential near-term approvals
2 actively recruiting trials targeting 3,626 patients
5 companies competing in this space